Catalogo dei prodotti della ricerca
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishImatinib mesylate is currently the standard therapy for chronic myeloid leukemia (CML) patients. Despite the remarkable results achieved with imatinib, the emergence of resistance to this drug has become a significant problem. Several strategies have been developed to overcome imatinib resistance, including dose escalation of the drug, combination treatments or novel targeted agents. Nilotinib is a second-generation tyrosine kinase inhibitor 30-50 fold more potent than imatinib with high affinity and selectivity on BCR/ABL, active against a wide range of mutant clones, except T315I mutation. Phase II trials of nilotinib showed high activity in imatinib-resistant or intolerant CML patients; front-line treatment of chronic phase Ph+ CML demonstrated rapid and stable cytogenetic responses and increasing molecular responses. We here review the development of nilotinib and the efficacy data in phase II and front-line trials.
Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL / Massimo, Breccia; Alimena, Giuliana. - In: CURRENT DRUG TARGETS. - ISSN 1389-4501. - STAMPA. - 10:6(2009), pp. 530-536.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
| Titolo: | Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL |
| Autori: | |
| Data di pubblicazione: | 2009 |
| Rivista: | |
| Citazione: | Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL / Massimo, Breccia; Alimena, Giuliana. - In: CURRENT DRUG TARGETS. - ISSN 1389-4501. - STAMPA. - 10:6(2009), pp. 530-536. |
| Handle: | http://hdl.handle.net/11573/32514 |
| Appartiene alla tipologia: | 01a Articolo in rivista |
File allegati a questo prodotto
Copyright © 2021